We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies, revised Privacy Policy and Terms of Service.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
Zimmer Biomet (ZBH) Beats on Q1 Earnings and Sales Estimates
Read MoreHide Full Article
Ever undergone reconstructive orthopedic surgery? Yes, then you may have been implanted with one of the personalized joint replacement technologies of Indiana-based, one of the leading orthopedic medical devices manufacturer–Zimmer Biomet Holdings, Inc. (ZBH - Free Report) , formerly known as Zimmer Holdings. In June 2015, legacy Zimmer completed the acquisition of Biomet for $14.0 billion. With operations in more than 25 countries, the company markets its orthopedic reconstructive, spinal and trauma devices, biologics, dental implants and related surgical products in more than 100 countries.
Currently, Zimmer Biomet has a Zacks Rank #3 (Hold) but that could change following its first quarter 2017 earnings report which has just released. (You can see the complete list of today’s Zacks #1 Rank (Strong Buy) stocks here). We have highlighted some of the key details from the just-released announcement below:
Earnings: The Zacks Consensus Estimate remained stands at $2.11 per share over the last 60 days. Zimmer Biomet’s adjusted earnings per share of $2.13 had surpassed this estimate by 1.4%.
Revenues: Zimmer Biomet posted revenues of $1.98 billion which has outpaced the Zacks Consensus Estimate for revenues of 1.96 billion.
Zimmer Biomet Holdings, Inc. Price and EPS Surprise
Key Stats: First-quarter revenues derived from Zimmer’s Knees segment were down 0.2% year over year to $701.8 million, while Hips recorded sales of $475.7 million, up 1.7% compared with the prior-year quarter. Revenues from S.E.T (Surgical, Sports Medicine, Foot and Ankle, Extremities and Trauma) improved 6.0% year over year to $425.1 million.
Major Factors: Zimmer Biomet’s first quarter revenue and adjusted earnings growth is consistent and met the company’s expectation. Per management, the company made improvements towards improving the global supply chain, in concert with ongoing, focused investments to complement and optimize the global manufacturing and quality systems. The company is focused in driving the priorities as it progresses further, although leveraging specialized sales channels and advancing the commercialization of differentiated clinical offerings. Also, management updated its full-year 2017 constant currency revenue and adjusted earnings per share guidance.
Stock Price: Following the earnings release, share prices did not show any movement in the pre-market trading session.
Check back later for our full write up on this Zimmer Biomet earnings report later!
Looking for Ideas with Even Greater Upside?
Most of Zacks’ investment ideas are short-term, directly based on our proven 1 to 3 month indicator. In addition, I invite you to consider our long-term opportunities. These rare trades look to start fast with strong Zacks Ranks, but carry through with double and triple-digit profit potential. Starting now, you can look inside our home run, value, and stocks under $10 portfolios, plus more.
Image: Bigstock
Zimmer Biomet (ZBH) Beats on Q1 Earnings and Sales Estimates
Ever undergone reconstructive orthopedic surgery? Yes, then you may have been implanted with one of the personalized joint replacement technologies of Indiana-based, one of the leading orthopedic medical devices manufacturer–Zimmer Biomet Holdings, Inc. (ZBH - Free Report) , formerly known as Zimmer Holdings. In June 2015, legacy Zimmer completed the acquisition of Biomet for $14.0 billion. With operations in more than 25 countries, the company markets its orthopedic reconstructive, spinal and trauma devices, biologics, dental implants and related surgical products in more than 100 countries.
Currently, Zimmer Biomet has a Zacks Rank #3 (Hold) but that could change following its first quarter 2017 earnings report which has just released. (You can see the complete list of today’s Zacks #1 Rank (Strong Buy) stocks here). We have highlighted some of the key details from the just-released announcement below:
Earnings: The Zacks Consensus Estimate remained stands at $2.11 per share over the last 60 days. Zimmer Biomet’s adjusted earnings per share of $2.13 had surpassed this estimate by 1.4%.
Revenues: Zimmer Biomet posted revenues of $1.98 billion which has outpaced the Zacks Consensus Estimate for revenues of 1.96 billion.
Zimmer Biomet Holdings, Inc. Price and EPS Surprise
Zimmer Biomet Holdings, Inc. Price and EPS Surprise | Zimmer Biomet Holdings, Inc. Quote
Key Stats: First-quarter revenues derived from Zimmer’s Knees segment were down 0.2% year over year to $701.8 million, while Hips recorded sales of $475.7 million, up 1.7% compared with the prior-year quarter. Revenues from S.E.T (Surgical, Sports Medicine, Foot and Ankle, Extremities and Trauma) improved 6.0% year over year to $425.1 million.
Major Factors: Zimmer Biomet’s first quarter revenue and adjusted earnings growth is consistent and met the company’s expectation. Per management, the company made improvements towards improving the global supply chain, in concert with ongoing, focused investments to complement and optimize the global manufacturing and quality systems. The company is focused in driving the priorities as it progresses further, although leveraging specialized sales channels and advancing the commercialization of differentiated clinical offerings. Also, management updated its full-year 2017 constant currency revenue and adjusted earnings per share guidance.
Stock Price: Following the earnings release, share prices did not show any movement in the pre-market trading session.
Check back later for our full write up on this Zimmer Biomet earnings report later!
Looking for Ideas with Even Greater Upside?
Most of Zacks’ investment ideas are short-term, directly based on our proven 1 to 3 month indicator. In addition, I invite you to consider our long-term opportunities. These rare trades look to start fast with strong Zacks Ranks, but carry through with double and triple-digit profit potential. Starting now, you can look inside our home run, value, and stocks under $10 portfolios, plus more.
Click here for a peek at this private information>>